Overview

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

Status:
Active, not recruiting

Trial end date:
2021-08-01

Target enrollment:

Participant gender:

Summary

This research study is evaluating how a drug called lenalidomide, given in combination with the standard chemotherapy regimen of Mitoxantrone, Etoposide, and Cytarabine, commonly referred to as MEC, works in individuals with either relapsed or refractory AML

Phase:

Phase 2

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

Celgene

Treatments:

Cytarabine
Etoposide
Etoposide phosphate
Lenalidomide
Mitoxantrone
Thalidomide